PSNL Personalis Genomics: Price-to-Projected Revenue Ratio

personalis.com (PSNL) - corporate logo

The expected P/S multiple correlates with the expansion of robotic capacities in sequencing laboratories, while the 21.30 indicator expresses the state of the metric. Personalis, Inc. (PSNL) relies on the integration of genomic platforms into medical protocols, creating stable demand. The strategy is based on the commercialization of precision tests for monitoring residual disease, enabling physicians to optimize targeted patient therapy.

PSNL Personalis: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

Personalis Genomics - analytical breakdowns and key metrics (PSNL)

- current price and projected stock value:
Stock Price Personalis|PSNL - Average Forecast Price
- company stock capitalization data:
Market Value Personalis Genomics|PSNL - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Personalis|PSNL - Book Valuation of Business|Market Value to Book Value Ratio personalis.com|PSNL - Company Assets
- debt and solvency information:
Debt to Equity Personalis, Inc.|PSNL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Personalis, Inc.|PSNL - Company Aggregate Debts|Debt to Book Capitalization Ratio Personalis Genomics|PSNL - Company Long-Term Debt|Company Short-Term Debts Personalis|Quick Liquidity personalis.com
- business earnings and investment ratios data:
PSNL - Net Financial Result|Future Profit Personalis, Inc.|PSNL - Company Value to Net Income|Forward P/E Multiple Personalis Corp|PSNL - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Personalis Genomics|PSNL - Operating profit before amortization|Net earnings per share (EPS TTM) Personalis|PSNL - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months personalis.com|PSNL - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Personalis, Inc.
- sales volume and revenue indicators:
PSNL - Company Annual Revenue|Company Projected Revenue Personalis|PSNL - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Personalis Genomics
Fundamental company analysis:PSNL (Personalis)
Original product of Personalis Genomics

This ratio determines the investment attractiveness of an asset through the lens of expected revenue growth. The metric compares the current market value of the company with projected sales volume, revealing the extent of the premium paid for future success. By analyzing the forward P/S indicator, an investor assesses market optimism regarding business scaling. For Personalis, Inc. (PSNL), such a valuation is supported by high customer switching costs due to the integration of unique genome sequencing into pharmaceutical research.

Who Personalis, Inc. competes with

Forward P/S Multiple ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD - Price-to-Projected Revenue Ratio|Forward Price to Sales AAPG (Ascentage Pharma Corp)|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|URGN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bicara Therapeutics|Market Cap to Future Revenue Ratio Erasca Inc ERAS|Price-to-Projected Revenue Ratio Delcath (DCTH)|Y-mAbs Corp - Market Cap to Projected Revenue|Forward P/S Multiple AURA (Aura Biosciences, Inc.)|Forward P/S Multiple Candel Therapeutics Inc. CADL|ARAY - Price-to-Projected Revenue Ratio|SLS: Price-to-Projected Revenue Ratio|ACTU: Forward P/S Multiple|CTOR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|protaratx.com (TARA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple FATE (Fate Therapeutics)|WHWK (aadibio.com) - Forward Price to Sales|Forward P/S Multiple TCRX (TScan Therapeutics, Inc.)|Market Cap to Expected Sales Ratio Champions Oncology Inc (CSBR)|XBIT - Price-to-Projected Revenue Ratio|CVM (CEL-SCI Corporation) - Market Cap to Projected Revenue|OSTX: Forward P/S Multiple|Forward Price-to-Revenue Multiple radiopharmtheranostics.com|Forward Price-to-Revenue Multiple ARTV|Adlai Nortye Limited (ANL) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Veru Inc. (VERU)|TPST: Future Price to Revenue|Price-to-Projected Revenue Ratio Xilio Therapeutics XLO|Market Cap to Expected Sales Ratio Renovaro Biosciences (RENB)|MURA - Price-to-Projected Revenue Ratio|KAPA (Kairos Pharma Ltd) - Market Cap to Projected Revenue|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|GDTC (CytoMed Therapeutics Limited) - Price-to-Projected Revenue Ratio|CRIS (Curis Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Apollomics Corp (APLM)|Forward P/S Multiple THAR|Forward P/S Multiple advanbiomed.com (ADVB)|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|CLDI: Market Cap to Projected Revenue|Sunshine Biopharma, Inc. - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|SLRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|Price-to-Projected Revenue Ratio American Oncology Network Inc|BGNE: Forward Price to Sales|Forward Price-to-Revenue Multiple CKPT (Checkpoint Therapeutics, Inc.)|ELEV (elevationoncology.com) - Forward Price to Sales|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|VIRX - Forward P/S Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple